Skip to main content
Erschienen in: Journal of Cancer Survivorship 6/2017

21.05.2017

Prostate cancer-related anxiety in long-term survivors after radical prostatectomy

verfasst von: Valentin H. Meissner, Kathleen Herkommer, Birgitt Marten-Mittag, Jürgen E. Gschwend, Andreas Dinkel

Erschienen in: Journal of Cancer Survivorship | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Knowledge of the psychological distress of long- and very long-term (>10 years) prostate cancer (PC) survivors is limited. This study intended to examine the parameters influencing anxiety related to prostate-specific antigen (PSA) and PC in long-term survivors after radical prostatectomy.

Methods

We surveyed 4719 PC survivors from the German multicenter prospective database “Familial Prostate Cancer.” We evaluated the association of PC-related anxiety (MAX-PC) with sociodemographic characteristics, family history of PC, global health status/quality of life (EORTC QLQ-C30), depression and anxiety (PHQ-2; GAD-2), latest PSA level, time since radical prostatectomy, and current therapy.

Results

The survey participants’ mean age was 75.2 years (SD = 6.5). Median follow-up was 11.5 years, and 19.5% of participants had survived more than 15 years since the initial treatment. The final regression analysis found that younger age, lower global health status/quality of life, higher depression and anxiety scores, higher latest PSA level, and shorter time since radical prostatectomy predicted increased PSA-related anxiety and PC anxiety. Familial PC was predictive only of PSA anxiety (all p < 0.05). The final model explained 12% of the variance for PSA anxiety and 24% for PC anxiety.

Conclusions

PC-related anxiety remained relevant many years after prostatectomy and was influenced by younger age, psychological status, rising PSA level, and shorter time since initial treatment.

Implications for Cancer Survivors

Survivors with these characteristics are at increased risk of PC-related anxieties, which should be considered by the treating physician during follow-up.
Literatur
1.
Zurück zum Zitat Zhou CK, Check DP, Lortet-Tieulent J, et al. Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group. Int J Cancer. 2016;138:1388–400.CrossRefPubMed Zhou CK, Check DP, Lortet-Tieulent J, et al. Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group. Int J Cancer. 2016;138:1388–400.CrossRefPubMed
2.
4.
Zurück zum Zitat Steinberg GD, Carter BS, Beaty TH, et al. Family history and the risk of prostate cancer. Prostate. 1990;17:337–47.CrossRefPubMed Steinberg GD, Carter BS, Beaty TH, et al. Family history and the risk of prostate cancer. Prostate. 1990;17:337–47.CrossRefPubMed
5.
Zurück zum Zitat Powell IJ, Meyskens FL. African American men and hereditary/familial prostate cancer: intermediate-risk populations for chemoprevention trials. Urology. 2001;57:178–81.CrossRefPubMed Powell IJ, Meyskens FL. African American men and hereditary/familial prostate cancer: intermediate-risk populations for chemoprevention trials. Urology. 2001;57:178–81.CrossRefPubMed
7.
Zurück zum Zitat Budäus L, Spethmann J, Isbarn H, et al. Inverse stage migration in patients undergoing radical prostatectomy: results of 8916 European patients treated within the last decade. BJU Int. 2011;108:1256–61.CrossRefPubMed Budäus L, Spethmann J, Isbarn H, et al. Inverse stage migration in patients undergoing radical prostatectomy: results of 8916 European patients treated within the last decade. BJU Int. 2011;108:1256–61.CrossRefPubMed
9.
Zurück zum Zitat Lassemillante AC, Doi SA, Hooper JD, et al. Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis. Endocrine. 2014;45:370–81.CrossRefPubMed Lassemillante AC, Doi SA, Hooper JD, et al. Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis. Endocrine. 2014;45:370–81.CrossRefPubMed
10.
11.
Zurück zum Zitat Olsson CE, Alsadius D, Pettersson N, et al. Patient-reported sexual toxicity after radiation therapy in long-term prostate cancer survivors. Br J Cancer. 2015;113:802–8.CrossRefPubMedPubMedCentral Olsson CE, Alsadius D, Pettersson N, et al. Patient-reported sexual toxicity after radiation therapy in long-term prostate cancer survivors. Br J Cancer. 2015;113:802–8.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Kopp RP, Marshall LM, Wang PY, et al. The burden of urinary incontinence and urinary bother among elderly prostate cancer survivors. Eur Urol. 2013;64:672–9.CrossRefPubMedPubMedCentral Kopp RP, Marshall LM, Wang PY, et al. The burden of urinary incontinence and urinary bother among elderly prostate cancer survivors. Eur Urol. 2013;64:672–9.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Gavin AT, Drummond JF, Donnelly C, et al. Patient-reported ‘ever had’ and ‘current’ long-term physical symptoms after prostate cancer treatments. BJU Int. 2015;116:397–406.CrossRefPubMedPubMedCentral Gavin AT, Drummond JF, Donnelly C, et al. Patient-reported ‘ever had’ and ‘current’ long-term physical symptoms after prostate cancer treatments. BJU Int. 2015;116:397–406.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Darwish-Yassine M, Berenji M, Wing D, et al. Evaluating long-term patient-centered outcomes following prostate cancer treatment: findings from the Michigan Prostate Cancer Survivor study. J Cancer Surviv. 2014;8:121–30.CrossRefPubMed Darwish-Yassine M, Berenji M, Wing D, et al. Evaluating long-term patient-centered outcomes following prostate cancer treatment: findings from the Michigan Prostate Cancer Survivor study. J Cancer Surviv. 2014;8:121–30.CrossRefPubMed
15.
Zurück zum Zitat van de Wal M, van Oort I, Schouten J, et al. Fear of cancer recurrence in prostate cancer survivors. Acta Oncol. 2016;55:821–7.CrossRefPubMed van de Wal M, van Oort I, Schouten J, et al. Fear of cancer recurrence in prostate cancer survivors. Acta Oncol. 2016;55:821–7.CrossRefPubMed
16.
Zurück zum Zitat Dahl S, Cvancarova M, Dahl AA, et al. Work ability in prostate cancer survivors after radical prostatectomy. Scand J Urol. 2016;50:116–22.CrossRefPubMed Dahl S, Cvancarova M, Dahl AA, et al. Work ability in prostate cancer survivors after radical prostatectomy. Scand J Urol. 2016;50:116–22.CrossRefPubMed
17.
Zurück zum Zitat Morris BB, Farnan L, Song L, et al. Treatment decisional regret among men with prostate cancer: racial differences and influential factors in the North Carolina Health Access and Prostate Cancer Treatment Project (HCaP-NC). Cancer. 2015;121:2029–35.CrossRefPubMed Morris BB, Farnan L, Song L, et al. Treatment decisional regret among men with prostate cancer: racial differences and influential factors in the North Carolina Health Access and Prostate Cancer Treatment Project (HCaP-NC). Cancer. 2015;121:2029–35.CrossRefPubMed
18.
Zurück zum Zitat Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8:268–78.CrossRefPubMed Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8:268–78.CrossRefPubMed
21.
Zurück zum Zitat Shen MJ, Nelson CJ, Peters E, et al. Decision-making processes among prostate cancer survivors with rising PSA levels: results from a qualitative analysis. Med Decis Mak. 2015;35:477–86.CrossRef Shen MJ, Nelson CJ, Peters E, et al. Decision-making processes among prostate cancer survivors with rising PSA levels: results from a qualitative analysis. Med Decis Mak. 2015;35:477–86.CrossRef
23.
Zurück zum Zitat Klotz LH. PSAdynia and other PSA-related syndromes: a new epidemic—a case history and taxonomy. Urology. 1997;50:831–2.CrossRefPubMed Klotz LH. PSAdynia and other PSA-related syndromes: a new epidemic—a case history and taxonomy. Urology. 1997;50:831–2.CrossRefPubMed
24.
Zurück zum Zitat Punnen S, Cowan JE, Chan JM, et al. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry. Eur Urol. 2015;68:600–8.CrossRefPubMed Punnen S, Cowan JE, Chan JM, et al. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry. Eur Urol. 2015;68:600–8.CrossRefPubMed
25.
Zurück zum Zitat Watts S, Leydon G, Birch B, et al. Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open. 2014;4:e003901.CrossRefPubMedPubMedCentral Watts S, Leydon G, Birch B, et al. Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open. 2014;4:e003901.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Sharp L, O’Leary E, Kinnear H, et al. Cancer-related symptoms predict psychological wellbeing among prostate cancer survivors: results from the PiCTure study. Psycho-Oncology. 2016;25:282–91.CrossRefPubMed Sharp L, O’Leary E, Kinnear H, et al. Cancer-related symptoms predict psychological wellbeing among prostate cancer survivors: results from the PiCTure study. Psycho-Oncology. 2016;25:282–91.CrossRefPubMed
27.
Zurück zum Zitat Dinkel A, Kornmayer M, Gschwend JE, et al. Influence of family history on psychosocial distress and perceived need for treatment in prostate cancer survivors. Familial Cancer. 2014;13:481–8.CrossRefPubMed Dinkel A, Kornmayer M, Gschwend JE, et al. Influence of family history on psychosocial distress and perceived need for treatment in prostate cancer survivors. Familial Cancer. 2014;13:481–8.CrossRefPubMed
28.
Zurück zum Zitat Tavlarides AM, Ames SC, Diehl NN, et al. Evaluation of the association of prostate cancer-specific anxiety with sexual function, depression and cancer aggressiveness in men 1 year following surgical treatment for localized prostate cancer. Psycho-Oncology. 2013;22:1328–35.CrossRefPubMed Tavlarides AM, Ames SC, Diehl NN, et al. Evaluation of the association of prostate cancer-specific anxiety with sexual function, depression and cancer aggressiveness in men 1 year following surgical treatment for localized prostate cancer. Psycho-Oncology. 2013;22:1328–35.CrossRefPubMed
29.
Zurück zum Zitat Roth A, Nelson CJ, Rosenfeld B, et al. Assessing anxiety in men with prostate cancer: further data on the reliability and validity of the Memorial Anxiety Scale for Prostate Cancer (MAX–PC). Psychosomatics. 2006;47:340–7.CrossRefPubMed Roth A, Nelson CJ, Rosenfeld B, et al. Assessing anxiety in men with prostate cancer: further data on the reliability and validity of the Memorial Anxiety Scale for Prostate Cancer (MAX–PC). Psychosomatics. 2006;47:340–7.CrossRefPubMed
30.
Zurück zum Zitat Roth AJ, Rosenfeld B, Kornblith AB, et al. The Memorial Anxiety Scale for Prostate Cancer. Validation of a new scale to measure anxiety in men with prosate cancer. Cancer. 2003;97:2910–8.CrossRefPubMed Roth AJ, Rosenfeld B, Kornblith AB, et al. The Memorial Anxiety Scale for Prostate Cancer. Validation of a new scale to measure anxiety in men with prosate cancer. Cancer. 2003;97:2910–8.CrossRefPubMed
31.
Zurück zum Zitat Venderbos LD, van den Bergh RC, Roobol MJ, et al. A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels. Psycho-Oncology. 2015;24:348–54.CrossRefPubMed Venderbos LD, van den Bergh RC, Roobol MJ, et al. A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels. Psycho-Oncology. 2015;24:348–54.CrossRefPubMed
32.
Zurück zum Zitat Tan HJ, Marks LS, Hoyt MA, et al. The relationship between intolerance of uncertainty and anxiety in men on active surveillance for prostate cancer. J Urol. 2016;195:1724–30.CrossRefPubMedPubMedCentral Tan HJ, Marks LS, Hoyt MA, et al. The relationship between intolerance of uncertainty and anxiety in men on active surveillance for prostate cancer. J Urol. 2016;195:1724–30.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Tavlarides AM, Ames SC, Thiel DD, et al. Baseline and follow-up association of the MAX-PC in men with newly diagnosed prostate cancer. Psycho-Oncology. 2015;24:451–7.CrossRefPubMed Tavlarides AM, Ames SC, Thiel DD, et al. Baseline and follow-up association of the MAX-PC in men with newly diagnosed prostate cancer. Psycho-Oncology. 2015;24:451–7.CrossRefPubMed
34.
Zurück zum Zitat Heck MM, Kron M, Gschwend JE, et al. Effect of family history on outcome in German patients treated with radical prostatectomy for clinically localised prostate cancer. Eur J Cancer. 2012;48:1312–7.CrossRefPubMed Heck MM, Kron M, Gschwend JE, et al. Effect of family history on outcome in German patients treated with radical prostatectomy for clinically localised prostate cancer. Eur J Cancer. 2012;48:1312–7.CrossRefPubMed
35.
Zurück zum Zitat Lehmann C, Mehnert A, Schulte T, et al. Erfassung krebs-und behandlungsspezifischer Ängste bei Prostatakrebspatienten in der Rehabilitation: Der Memorial Angst-Fragebogen für Prostatakrebs (MAX-PC). Praxis Klinische Verhaltensmedizin und Rehabilitation. 2006;19:345–52. Lehmann C, Mehnert A, Schulte T, et al. Erfassung krebs-und behandlungsspezifischer Ängste bei Prostatakrebspatienten in der Rehabilitation: Der Memorial Angst-Fragebogen für Prostatakrebs (MAX-PC). Praxis Klinische Verhaltensmedizin und Rehabilitation. 2006;19:345–52.
36.
Zurück zum Zitat Mehnert A, Lehmann C, Schulte T, et al. Presence of symptom distress and prostate cancer-related anxiety in patients at the beginning of cancer rehabilitation. Onkologie. 2007;30:551–6.PubMed Mehnert A, Lehmann C, Schulte T, et al. Presence of symptom distress and prostate cancer-related anxiety in patients at the beginning of cancer rehabilitation. Onkologie. 2007;30:551–6.PubMed
37.
Zurück zum Zitat Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.CrossRefPubMed Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.CrossRefPubMed
38.
Zurück zum Zitat Kroenke K, Spitzer RL, Williams JB, et al. An ultra-brief screening scale for anxiety and depression: the PHQ–4. Psychosomatics. 2009;50:613–21.PubMed Kroenke K, Spitzer RL, Williams JB, et al. An ultra-brief screening scale for anxiety and depression: the PHQ–4. Psychosomatics. 2009;50:613–21.PubMed
39.
Zurück zum Zitat Löwe B, Wahl I, Rose M, et al. A 4-item measure of depression and anxiety: validation and standardization of the Patient Health Questionnaire-4 (PHQ-4) in the general population. J Affect Disord. 2010;122:86–95.CrossRefPubMed Löwe B, Wahl I, Rose M, et al. A 4-item measure of depression and anxiety: validation and standardization of the Patient Health Questionnaire-4 (PHQ-4) in the general population. J Affect Disord. 2010;122:86–95.CrossRefPubMed
40.
Zurück zum Zitat Lamers RE, Cuypers M, Husson O, et al. Patients are dissatisfied with information provision: perceived information provision and quality of life in prostate cancer patients. Psycho-Oncology. 2016;25:633–40.CrossRefPubMed Lamers RE, Cuypers M, Husson O, et al. Patients are dissatisfied with information provision: perceived information provision and quality of life in prostate cancer patients. Psycho-Oncology. 2016;25:633–40.CrossRefPubMed
41.
Zurück zum Zitat Violan C, Foguet-Boreu Q, Flores-Mateo G, et al. Prevalence, determinants and patterns of multimorbidity in primary care: a systematic review of observational studies. PLoS One. 2014;9:e102149.CrossRefPubMedPubMedCentral Violan C, Foguet-Boreu Q, Flores-Mateo G, et al. Prevalence, determinants and patterns of multimorbidity in primary care: a systematic review of observational studies. PLoS One. 2014;9:e102149.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Vissers PA, Thong MS, Pouwer F, et al. The impact of comorbidity on health-related quality of life among cancer survivors: analyses of data from the PROFILES registry. J Cancer Surviv. 2013;7:602–13.CrossRefPubMed Vissers PA, Thong MS, Pouwer F, et al. The impact of comorbidity on health-related quality of life among cancer survivors: analyses of data from the PROFILES registry. J Cancer Surviv. 2013;7:602–13.CrossRefPubMed
43.
Zurück zum Zitat Drummond FJ, Kinnear H, O’Leary E, et al. Long-term health-related quality of life of prostate cancer survivors vary by primary treatment. Results from the PiCTure (Prostate Cancer Treatment, your experience) study. J Cancer Surviv. 2015;9:361–72.CrossRefPubMed Drummond FJ, Kinnear H, O’Leary E, et al. Long-term health-related quality of life of prostate cancer survivors vary by primary treatment. Results from the PiCTure (Prostate Cancer Treatment, your experience) study. J Cancer Surviv. 2015;9:361–72.CrossRefPubMed
44.
Zurück zum Zitat Banks E, Byles JE, Gibson RE, et al. Is psychological distress in people living with cancer related to the fact of diagnosis, current treatment or level of disability? Findings from a large Australian study. Med J Aust. 2010;193(5 Suppl):S62–7.PubMed Banks E, Byles JE, Gibson RE, et al. Is psychological distress in people living with cancer related to the fact of diagnosis, current treatment or level of disability? Findings from a large Australian study. Med J Aust. 2010;193(5 Suppl):S62–7.PubMed
45.
Zurück zum Zitat Roth A, Passik S. Anxiety in men with prostate cancer may interfere with effective management of the disease. Primary Care Cancer. 1996;16:30. Roth A, Passik S. Anxiety in men with prostate cancer may interfere with effective management of the disease. Primary Care Cancer. 1996;16:30.
46.
Zurück zum Zitat Lofters A, Juffs HG, Pond GR, et al. “PSA-itis”: knowledge of serum prostate specific antigen and other causes of anxiety in men with metastatic prostate cancer. J Urol. 2002;168:2516–20.CrossRefPubMed Lofters A, Juffs HG, Pond GR, et al. “PSA-itis”: knowledge of serum prostate specific antigen and other causes of anxiety in men with metastatic prostate cancer. J Urol. 2002;168:2516–20.CrossRefPubMed
47.
Zurück zum Zitat Hillen MA, de Haes HC, Smets EM. Cancer patients’ trust in their physician—a review. Psycho-Oncology. 2011;20:227–41.CrossRefPubMed Hillen MA, de Haes HC, Smets EM. Cancer patients’ trust in their physician—a review. Psycho-Oncology. 2011;20:227–41.CrossRefPubMed
48.
Zurück zum Zitat Albright F, Stephenson RA, Agarwal N, et al. Prostate cancer risk prediction based on complete prostate cancer family history. Prostate. 2015;75:390–8.CrossRefPubMed Albright F, Stephenson RA, Agarwal N, et al. Prostate cancer risk prediction based on complete prostate cancer family history. Prostate. 2015;75:390–8.CrossRefPubMed
49.
Zurück zum Zitat Spencer BA, Babey SH, Etzioni DA, et al. A population-based survey of prostate-specific antigen testing among California men at higher risk for prostate carcinoma. Cancer. 2006;106:765–74.CrossRefPubMed Spencer BA, Babey SH, Etzioni DA, et al. A population-based survey of prostate-specific antigen testing among California men at higher risk for prostate carcinoma. Cancer. 2006;106:765–74.CrossRefPubMed
50.
Zurück zum Zitat Meiser B, Cowan R, Costello A, et al. Prostate cancer screening in men with a family history of prostate cancer: the role of partners in influencing men’s screening uptake. Urology. 2007;70:738–42.CrossRefPubMed Meiser B, Cowan R, Costello A, et al. Prostate cancer screening in men with a family history of prostate cancer: the role of partners in influencing men’s screening uptake. Urology. 2007;70:738–42.CrossRefPubMed
51.
Zurück zum Zitat Cohen L, Fouladi RT, Babaian RJ, et al. Cancer worry is associated with abnormal prostate-specific antigen levels in men participating in a community screening program. Cancer Epidemiol Biomark Prev. 2003;12:610–7. Cohen L, Fouladi RT, Babaian RJ, et al. Cancer worry is associated with abnormal prostate-specific antigen levels in men participating in a community screening program. Cancer Epidemiol Biomark Prev. 2003;12:610–7.
Metadaten
Titel
Prostate cancer-related anxiety in long-term survivors after radical prostatectomy
verfasst von
Valentin H. Meissner
Kathleen Herkommer
Birgitt Marten-Mittag
Jürgen E. Gschwend
Andreas Dinkel
Publikationsdatum
21.05.2017
Verlag
Springer US
Erschienen in
Journal of Cancer Survivorship / Ausgabe 6/2017
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-017-0619-y

Weitere Artikel der Ausgabe 6/2017

Journal of Cancer Survivorship 6/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.